AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
Ladenburg, Germany, 4 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, will be presented at the 22st International Myeloma Society (IMS) Annual Meeting, being held in Toronto, Canada, on 17 to […]
Firstly, congratulations to the team at Verona Pharma on their incredible $10bn dollar deal with Merck! And to Actithera on their oversubscribed $75.5M Series A – a great achievement in the current market. Huge congratulations also go to the incomparable Clive Cookson on receiving the Lifetime Achievement Award at the Association of British Science Writers […]
#AI has been making the headlines again this week, with a bold announcement from the UK government that it could be used to fix the many potholes that pepper Britain’s roads. But beyond politics, there’s an ongoing narrative in life sciences about the growing role of AI across the clinical development process. Perhaps the most […]
This week showcased the diverse projects and research that Optimum’s clients are involved with. These included STORM Therapeutics’ groundbreaking research into METTL3, an exciting new target in cancer therapy that was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, the biggest oncology meeting in the world. In the same week, our client […]
